Reported Sunday, HUTCHMED Doses First Patient In Phase Ia Dose Escalation Of First-In-Class HMPL-A830 To Determine Maximum Tolerated Dose In Advanced Solid Tumors

Loading news article.

Reported Sunday, HUTCHMED Doses First Patient In Phase Ia Dose Escalation Of First-In-Class HMPL-A830 To Determine Maximum Tolerated Dose In Advanced Solid Tumors | WAPE

Reported Sunday, HUTCHMED Doses First Patient In Phase Ia Dose Escalation Of First-In-Class HMPL-A830 To Determine Maximum Tolerated Dose In Advanced Solid Tumors

Article summary

Related companies

Comments —